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Abstract
Many immune correlates of CD8
+ T-cell-mediated control of HIV replication, including polyfunctionality, proliferative ability,
and inhibitory receptor expression, have been discovered. However, no functional correlates using ex vivo cells have been
identified with the known ability to cause the direct elimination of HIV-infected cells. We have recently discovered the ability
of human CD8
+ T-cells to rapidly upregulate perforin—an essential molecule for cell-mediated cytotoxicity—following
antigen-specific stimulation. Here, we examined perforin expression capability in a large cross-sectional cohort of chronically
HIV-infected individuals with varying levels of viral load: elite controllers (n=35), viremic controllers (n=29), chronic
progressors (n=27), and viremic nonprogressors (n=6). Using polychromatic flow cytometry and standard intracellular
cytokine staining assays, we measured perforin upregulation, cytokine production, and degranulation following stimulation
with overlapping peptide pools encompassing all proteins of HIV. We observed that HIV-specific CD8
+ T-cells from elite
controllers consistently display an enhanced ability to express perforin directly ex vivo compared to all other groups. This
ability is not restricted to protective HLA-B haplotypes, does not require proliferation or the addition of exogenous factors,
is not restored by HAART, and primarily originates from effector CD8
+ T-cells with otherwise limited functional capability.
Notably, we found an inverse relationship between HIV-specific perforin expression and viral load. Thus, the capability of
HIV-specific CD8
+ T-cells to rapidly express perforin defines a novel correlate of control in HIV infection.
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Introduction
Approximately 35–40 million people are currently infected with
HIV worldwide. Most of these individuals fail to control HIV
replication, and ultimately progress to acquired immune deficiency
syndrome (AIDS) if left untreated. However, a subset (,1%) of the
HIV-infected population, termed elite controllers (EC), can
spontaneously control viral replication to undetectable levels
[1,2,3]. Understanding the mechanisms of immunologic control
of HIV replication in EC may identify candidate markers of
immune control useful for assessing HIV vaccine strategies.
The host immune response, in particular HIV-specific CD8
+ T-
cells, is at least partially responsible for the control of viral
replication in many EC. For example, EC are enriched for certain
HLA alleles, such as HLA-B13, B15, B51, B27, B57, and B58
[4,5,6,7]. EC contain a greater fraction of HIV-specific CD8
+ T-
cells that can degranulate, produce multiple functional cytokines
and chemokines and display markedly better proliferative potential
upon HIV peptide stimulation than individuals with progressive
disease [7,8,9,10,11,12,13]. Additionally, recent evidence has
demonstrated that HIV-specific CD8
+ T-cells from EC have
enhanced cytotoxic capabilities compared to progressors: Several
groups have shown that HIV-specific CD8
+ T-cells from EC
display a superior ability to suppress the replication of HIV during
extended culture [14,15,16]. Using CD8
+ T-cells expanded in vitro
for six days, Migueles and colleagues observed a higher cytotoxic
capacity on a per-cell basis of HIV-specific CD8
+ T-cells from EC
[17]. Collectively, these findings suggest that CD8
+ T-cells may be
critical to the control of HIV replication in vivo.
CD8
+ T-cells are thought to kill virally-infected cells predom-
inantly through the release of lytic proteins - mainly perforin and
granzymes - that are secreted via exocytosis of pre-formed granules
following recognition of infected targets [18,19,20]. Granule-
mediated killing by CD8
+ T-cells occurs within minutes to hours of
PLoS Pathogens | www.plospathogens.org 1 May 2010 | Volume 6 | Issue 5 | e1000917target cell recognition; however, the reconstitution of intracellular
perforin following degranulation has been reported to first require
cellular proliferation [13,21,22]. We have recently identified
another mechanism by which perforin-mediated CD8
+ T-cell
killing can take place: the rapid upregulation and targeted release
of newly produced perforin, which traffics to the immunological
synapse via a route that largely bypasses cytotoxic granules [23].
De novo synthesis of perforin by human CD8
+ T-cells can be
detected by flow cytometry in conjunction with standard
intracellular cytokine-staining (ICS) [24], thus permitting simulta-
neous assessment of CD8
+ T-cell cytotoxic potential and cytokine
production.
Here, we measured the ability of HIV-specific CD8
+ T-cells to
express perforin in a cross-sectional cohort of chronically-infected
individuals that differentially control viral replication. Several
previously published studies have examined perforin expression in
HIV-specific CD8
+ T-cells in both progressive and nonprogressive
infection [13,25,26,27]. However, due to the nature of the anti-
perforin antibody employed [23], these studies have uniformly
assessed only pre-formed, granule-associated perforin present
within resting or long-term activated HIV-specific CD8
+ T-cells.
In this work we demonstrate that HIV-specific CD8
+ T-cells from
EC, compared to progressors, have a superior ability to express
perforin immediately upon activation, without the need for prior
proliferation or the addition of exogenous cytokines. Overall, this
work identifies the rapid expression of perforin as a novel correlate
of control of HIV replication and urges a closer examination of
CD8
+ T-cell polyfunctionality in HIV infection.
Results
HIV-specific CD8
+ T-cell response between EC and CP did
not vary greatly in total magnitude, degranulation, or
cytokine production
We assessed the magnitude and functional characteristics of
HIV-specific CD8
+ T-cells by stimulating PBMC from 35 elite
controllers (EC), 29 viremic controllers (VC), and 27 chronic
progressors (CP) [Table 1 and Table S1] with overlapping peptide
pools encompassing all HIV-1 (clade B) proteins. We developed a
flow cytometric staining panel (Fig. S1A) that simultaneously
measured memory phenotype (CD27, CD45RO, and CD57),
degranulation [surface expression of CD107a [28]], cytokine
expression (IFN-c, TNFa, and IL-2), and chemokine production
(MIP1a). As a sixth functional parameter, we included an anti-
perforin antibody (clone B-D48) to measure perforin upregulation
[23,24]. As shown in Figure S1B, the historically used antibody
(dG9 clone) cannot detect perforin expression within activated
CD8
+ T-cells in the same ICS assay format.
As shown in Figure 1A, the total HIV-specific CD8
+ T-cell
response magnitude to Pol, Env, Nef, or TRVVV stimulation did
not differ substantively across the groups, but EC displayed a
somewhat higher Gag-specific response. The lack of large
differences in response magnitude is in agreement with previous
studies that measured the total magnitude of CD8
+ T-cell
responses in EC and CP using flow cytometry [7,8,13]. We next
determined the relative contribution of CD107a, IFN-c, TNFa,
IL-2, and MIP1a to the HIV-specific CD8
+ T-cell response
(Fig. 1B). In general, no clear trends emerged in overall
functionality between the groups. For example, compared to
EC, CP demonstrated a slightly enhanced ability to degranulate,
lower levels of TNFa, but no statistically significant difference in
the proportion of the average HIV-specific CD8
+ T-cell response
comprised of either IFN-c or MIP1a. The largest difference in
functionality was IL-2 expression, which was higher among EC
and VC compared to CP. Previous studies have also shown
Author Summary
While the majority HIV-infected individuals progress to
AIDS, a fraction of these individuals—for reasons not
completely understood—do not develop AIDS and also
display sustained control over viral replication; these
subjects are sometimes referred to as elite controllers
(EC). Prior evidence has shown that HIV-specific CD8
+ T-
cells, a component of adaptive immunity against intracel-
lular pathogens, from EC exhibit enhanced functionality
compared to individuals with progressive disease. There-
fore, HIV-specific CD8
+ T-cells likely play an important role
in the favorable clinical outcomes witnessed in EC. We
show in this study that the ability to control HIV replication
in EC is associated with the expression of a protein called
perforin, a critical molecule that enables CD8
+ T-cells to
directly kill infected cells - thereby preventing the spread
of HIV to previously uninfected cells. In infected subjects
with nonprogressive disease, we show that HIV-specific
CD8
+ T-cells demonstrate a superior ability to express
perforin upon antigen-specific stimulation, whereas in
progressors this property is diminished. Thus, we identify a
functional capability of CD8
+ T-cells, readily measured by
standard intracellular cytokine staining assays, that poten-
tially has a direct impact on HIV replication in vivo. These
findings may, therefore, provide an important qualifier for
future HIV vaccine research.
Table 1. Clinical parameters of HIV infected subject cohorts.
Patient Characteristics Elite Controller Viremic Controller Chronic Progressor Viremic Nonprogressor HAART-treated
Number of subjects 35 29 27 6 15
Plasma HIV RNA, median (IQR),
copies/mL
undetectable 396 (82–874) 24,121 (18,000–41,579) 35,000 (29,672–101,500) undetectable
CD4
+ T-cell count, median (IQR),
cells/mm
3
811 (702–1,068) 576 (449–785) 508 (401–599) 557 (439–625) 440 (301–610)
Decline in CD4
+ T-cell count per year,
median (IQR), cells/mm
3
Not determined Not determined 170 (103–319) 36 (26–47) Not determined
Infection duration, median (IQR), years 17 (13–21) 12 (8–19) 7 (4–13) 20 (16–22) 16 (12–20)
Duration of HAART treatment prior to
PBMC sample, median (IQR), years
N/A N/A N/A N/A 2 (1–6)
doi:10.1371/journal.ppat.1000917.t001
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+ T-cells in EC demonstrate an enhanced ability to express perforin compared to CP. (A) The CD8
+ T-cell
response magnitude to all HIV peptide pools was calculated for EC, VC, and CP and plotted as percent of CD8
+ T-cells (excluding naı ¨ve cells). The total
magnitude was calculated by summing across all functional combinations. (A) The proportion of the average HIV-specific CD8
+ T-cell response
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subjects with low or undetectable viremia [7,8,10]. Similar overall
observations were found for the individual HIV antigens as well
(data not shown).
HIV-specific CD8
+ T-cells in EC demonstrated a greater
ability to express perforin than VC and CP
We next assessed perforin expression by HIV-specific CD8
+ T-
cells in each cohort group. We consistently observed higher co-
expression of perforin within responding cells from EC compared
to VC or CP for all HIV antigens (Fig. 1C shows representative
Nef-specific responses producing IFN-c; other HIV antigens are
not shown but yielded similar results). In fact, perforin expression
comprised a significantly greater proportion of the average HIV-
specific CD8
+ T-cell response in EC than in CP (Fig. 1D). The
relative contribution of perforin to the CD8
+ T-cell response was
significantly higher (,3 fold) in EC compared to CP for all of the
individual HIV antigens (Fig. 1E). In addition to the proportion of
the HIV-specific CD8
+ T-cell response comprised of perforin, EC
also displayed a greater magnitude of perforin expression upon
stimulation by all HIV antigen pools compared to both VC and
CP (Fig. S2). However, we found no correlation among EC
between the total magnitude of an HIV-specific response and the
corresponding amount of perforin expression (Fig. S3).
As shown in Figure S4, there was, however, some variability
among EC subjects in the contribution of perforin to the HIV-
specific CD8
+ T-cell response. Within some EC there was low
perforin expression induced by one HIV antigen (e.g. Gag) but
higher perforin production to another peptide pool (e.g. Pol).
Some EC demonstrated high HIV-specific perforin in response to
every antigen. Although several EC did express low levels of HIV-
specific perforin, only 20% of all EC in the cohort failed to achieve
30% perforin for the CD8
+ T-cell response to at least one of the
antigen pools (data not shown). In contrast, only 15% of CP
demonstrated even one HIV antigen-specific CD8
+ T-cell
response comprised of 30% perforin (data not shown). Thus, our
data suggests that EC are not simply a homogenous group of HIV-
infected individuals and do demonstrate some variability, which is
in agreement with previous findings [7,29].
Next, we examined the functional profile of the average Nef-
specific CD8
+ T-cell response among the EC, VC, and CP groups
(Fig. 2A and 2B; the other HIV antigens are not shown but yielded
similar results). Only the functional combinations that were
significantly different between at least two of the groups are
shown in Figure 2A; all 64 combinations are shown in Figure S5.
We rarely observed simultaneous expression of all six functions
because perforin and IL-2 are generally not co-expressed by the
same cell [30]. The average Nef-specific functional profile in EC
and VC was composed of more CD8
+ T-cells than in CP that
simultaneously expressed five functions (Fig. 2B). Additionally, the
percentage of the Nef-specific response that was perforin-positive
(black arcs in Fig. 2B) was significantly higher among EC (44%)
compared to VC (27%; p,0.05) or CP (14%; p,0.001). Similar
findings were observed for Gag-, Pol-, Env-, and TRVVV-specific
responses (data not shown).
The majority of perforin was produced by cells expressing only
a single other function: CD107a or MIP1a (Fig. 2B). The CD8
+ T-
cells that co-expressed CD107a and perforin likely upregulated
perforin de novo since a cell that was CD107a
+ presumably lost all
(or nearly all) of its granule-associated perforin through the process
of degranulation. As shown in Figure S6, the proportion of the
HIV-specific response in EC that was both CD107a
+ and
perforin
+ was significantly higher than CP for all HIV antigens.
The second major population of perforin
+ cells co-expressed only
MIP1a. The relevance of this population is unclear. However, we
have previously shown that activated CD8
+ T-cells can transport
newly synthesized perforin directly to the immunological synapse
without trafficking first through cytolytic granules [23]. Thus,
despite the absence of apparent degranulation, MIP1a
+ perforin
+
cells may potentially be involved in ongoing cytolytic activity.
Perforin expression is not restricted to the presence of
protective HLA-B alleles
One consistent host factor associated with durable control of
HIV is the presence of certain HLA class I alleles, particularly
HLA-B27 and B57 [1,4,31,32,33]. Other HLA-B alleles have also
been associated with delayed disease progression or lower viral
loads, including HLA-B13, B15, B51, and B58 [5,6]. Among EC
in our cohort, 54% of the subjects expressed HLA-B27 or B57,
while 32% of VC carried these alleles (data not shown).
Additionally, 43% of EC in the study cohort expressed either
HLA-B13, B15, B51, or B58, while 32% of VC carried these
alleles (data not shown). As shown in Figures 3A and S7, we found
no association between protective HLA-B status and perforin
expression to any HIV peptide pool in either EC or VC (Gag
shown in Fig. 3A, Nef shown in Fig. S7, and data not shown), or
when perforin expression to all HIV peptide pools was averaged
within each subject (Fig. 3B). Thus, there was no apparent
relationship between protective HLA-B alleles and the capacity of
HIV-specific CD8
+ T-cells to express perforin after stimulation.
Distinct expansion of HIV-specific effector CD8
+ T-cells in
EC
We next examined the memory phenotype, based on surface
expression of CD27, CD45RO, and CD57, of HIV-specific CD8
+
T-cells in each group. The majority of HIV-specific CD8
+ T-cells
that expressed perforin in EC, VC, and CP were
CD27
-CD45RO
-CD57
+/- (Fig. 4A and 4B and data not shown),
commonly considered an effector-type profile, which is in
agreement with previous reports that examined the presence of
perforin in various human CD8
+ T-cell memory subsets [34,35].
This phenotype was common to virtually all perforin
+ HIV-
specific CD8
+ T-cells regardless of their specificity for Gag, Pol,
Nef, Env or TRVVV (Fig. 4A and data not shown). HIV-specific
CD8
+ T-cells among many CP subjects were skewed toward a
CD27
+CD45RO
+/- memory phenotype (Fig. 4C), as previously
comprised of each single functional parameter (except perforin) is shown for EC, VC, and CP. (C) Representative flow cytometric plots of perforin
versus IFN-c are shown from one representative EC, VC, and CP. Percentages represent the proportion of functional cells that stain either positive or
negative for perforin. Values in parentheses are the magnitude of each population and denote percent of CD8
+ T-cells (excluding naı ¨ve cells). All
reported values have been corrected for background. (D) The proportion of the average HIV-specific CD8
+ T-cell response comprised of perforin is
shown for EC, VC, and CP. (E) The relative contribution of perforin to the Gag-, Pol-, Env-, Nef-, and TRVVV-specific CD8
+ T-cell responses is shown for
EC, VC, and CP. (A, B, D, E) Statistical analysis was carried out using one-way ANOVA tests (nonparametric; Kruskal-Wallis) followed by a Dunns test for
multiple comparisons. * denotes a p value ,0.05, ** denotes a p value,0.01, and *** denotes a p value ,0.001. All bars represent the mean and error
bars indicate the standard deviation.
doi:10.1371/journal.ppat.1000917.g001
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CD8
+ T-cells in EC than in CP displayed a memory phenotype
consistent with highly differentiated effector cells (Fig. 4C).
Overall, the presence of CD27
-CD45RO
- HIV-specific CD8
+ T-
cells was less common among CP than EC (Fig. S8) in agreement
with a previous study [14]. The absence of effector-like HIV-
specific CD8
+ T-cells in CP is not, however, reflective of the total
CD8
+ T-cell pool in these individuals. A substantial fraction of
CD8
+ T-cells in CP that responded to CEF stimulation were
CD27
-CD45RO
- (Fig. 4D). However, responding Gag-specific
CD8
+ T-cells within the same subjects were primarily
CD27
+CD45RO
+ (Fig. 4D).
Inverse relationship between HIV-specific perforin
expression and viral load
Having observed higher perforin expression in HIV-specific
CD8
+ T-cells in EC, we next examined the relationship between
perforin expression and viral load. We found a significant inverse
correlation between the average HIV-specific perforin expression
within each subject and HIV viral load (Fig. 5A). This inverse
relationship was found for every individual HIV antigen specificity
(data not shown) and when only considering subjects with
detectable viremia (EC subjects excluded; Fig. S9). We also found
a statistically significant positive correlation between CD4
+ T-cell
counts in the blood and HIV-specific perforin expression by CD8
+
Figure 2. The majority of perforin expression comes from cells with otherwise limited functional capability. (A) The functionality of the
average Nef-specific CD8
+ T-cell response is shown; only the functional permutations that varied significantly between at least two of the groups are
shown. ** denotes a p value ,0.01 based on a Lachenbruch’s Two-part Wilcoxon test as described in the Methods. All bars represent the mean and
error bars indicate the standard deviation. (B) The average Nef-specific CD8
+ T-cell functional profile is shown for EC, VC, and CP. Responses are
grouped according to the number of positive functions. The relative amount of perforin positivity within each functional group (i.e. each pie slice) is
depicted as black arcs. The relative contribution of perforin (mean value) to the entire response is represented by the percentage in the center of
each pie.
doi:10.1371/journal.ppat.1000917.g002
Rapid Perforin Expression and Control of HIV
PLoS Pathogens | www.plospathogens.org 5 May 2010 | Volume 6 | Issue 5 | e1000917T-cells across all subjects (Fig. S10), a finding most likely driven by
the high CD4
+ T-cell counts among the EC subjects (Table 1).
Furthermore, when we examined the other functional parameters
in a similar manner, we only found a statistically significant inverse
relationship between IL-2 expression and viral load (Fig. S11),
which is an expected result based upon previous studies.
To better understand the relationship between viral load and
perforin expression, we next compared HIV-specific CD8
+ T-cell
responses among EC to viremic nonprogressors (VNP), who
maintain stable CD4
+ T-cell counts in the face of consistently high
viral loads (median 35,000 viral RNA copies/mL plasma; Table 1)
without progressing to AIDS. The infection duration in both
groups was similar (17 vs. 20 years in the absence of therapy;
Table 1). Therefore, by comparing these two groups, we can
control for the rate of CD4
+ T-cell decline, progression rate, and
duration of infection. As shown in Figure 5B, perforin expression
by HIV-specific CD8
+ T-cells in VNP is significantly lower than
EC and actually closely resembles the perforin levels observed in
CP. Together, these data indicate that the degree of HIV-specific
CD8
+ T-cell perforin expression is predictive of the ability to
control viral load independent of the rate of CD4
+ T-cell decline,
progression status, or infection duration.
HIV-specific perforin expression is not recovered by
HAART
In order to determine whether the low perforin expression
associated with progression was reversible, we examined HIV-
specific perforin expression by CD8
+ T-cells in HAART-treated
individuals with undetectable HIV viremia (Table 1). Compared
to EC, the total CD8
+ T cell response magnitude was lower in
HAART-treated subjects to Gag, Pol, and Nef stimulation;
however, only the difference in the total Gag-specific magnitude
reached statistical significance (Fig. S12). Despite some differences
in total magnitude, there were no substantive differences in the
relative contribution of degranulation, IFN-c, TNFa, or MIP1a
production (Fig. S13). However, HIV-specific perforin expression
in HAART-suppressed subjects was considerably lower than EC,
and was similar to the levels observed in CP (Fig. 5B). Thus, the
ability to express and rapidly upregulate perforin by HIV-specific
CD8
+ T-cells in chronic HIV infection is not recovered following
HAART.
Discussion
While many cell surface markers, activation profiles, and
functional parameters of both ex vivo HIV-specific CD8
+ and
CD4
+ T-cells have been shown to correlate with control of viremia
[8,38,39,40,41,42], few, if any, can potentially mediate direct
control of HIV replication through the lysis of infected cells. Here
we have shown that perforin expression by ex vivo HIV-specific
CD8
+ T-cells is significantly higher in EC compared to patients
with uncontrolled viral replication. HIV-specific CD8
+ T-cells that
express perforin bear predominantly an effector phenotype,
indicating that effector populations, in addition to central memory
populations [43,44], may be critically important to the control of
HIV infection. We also find an inverse correlation between
perforin expression by HIV-specific CD8
+ T-cells and viral load.
Together, these results represent an unique assessment of HIV-
specific immunity and provide a novel platform for measuring
potential vaccine efficacy in clinical trials.
There is little question regarding the crucial importance of
perforin in the control of infectious pathogens. Indeed, mutation
or dysregulation of perforin in humans results in compromised
cellular immunity and enhanced susceptibility to viral infections
[45]. Previous reports on ex vivo HIV-specific CD8
+ T-cells have
uniformly found low or absent perforin expression in both CP and
EC and no detectable differences in perforin levels between the
groups [13,25,27,37,46]. However, these studies have in retrospect
only defined the level of granule-associated perforin within resting
HIV-specific CD8
+ T-cells due to unforeseen limitations in the
anti-perforin antibody employed in these studies [23,24]. Due to
chronic activation and continual presence of viral antigen - albeit
extremely low levels in EC [47] - HIV-specific CD8
+ T-cells are
unlikely to reach a true resting state; therefore, it is unlikely these
cells accumulate cytolytic granules containing perforin in vivo.
However, our results indicate that this does not preclude their
Figure 3. Perforin expression is not restricted to the presence
of protective HLA-B alleles. EC were stratified based on the
expression of HLA-B alleles previously shown to be associated with
improved clinical outcomes. The relative amount of perforin expression
is shown for the (A) Gag-specific and (B) average HIV-specific CD8
+ T-
cell responses among all EC. Each symbol represents an individual study
subject. Some of the symbols are colored to denote the presence of
another protective HLA-B allele: blue, HLA-B13; green, HLA-B15; orange,
HLA-B51; red, HLA-B58. No statistically significant differences were
found between the groups using a one-way ANOVA test (nonparamet-
ric; Kruskal-Wallis) followed by a Dunns test for multiple comparisons.
The error bars represent the mean and standard deviation.
doi:10.1371/journal.ppat.1000917.g003
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tion, a killing mechanism that we have recently shown potentiates
the cytotoxic ability of human CD8
+ T-cells [23].
We have shown previously that both the commonly used anti-
perforin antibody (dG9 clone) and the anti-perforin antibody used
in this study (B-D48 clone) stain resting CD8
+ T-cells equivalently
[24]. Thus, previous research that found no difference in the levels
of perforin within resting HIV-specific CD8
+ T-cells between EC
and CP [13,25,27,37,46] were not necessarily incorrect. Here, we
have shown using a perforin antibody that can detect both
granule-associated and granule-independent forms of perforin that
HIV-specific CD8
+ T-cells from EC express this protein to a
higher degree than patients with uncontrolled viremia. It is
important to note, though, that the B-D48 clone cannot
specifically distinguish pre-formed from newly upregulated
perforin using flow cytometric-based assays. Nevertheless, to
identify the potential contribution of perforin produced de novo,
we examined the proportion of the HIV-specific CD8
+ T-cell
Figure 4. Distinct expansion of HIV-specific effector CD8
+ T-cells in EC. (A) Gag-, Pol-, and Nef-specific perforin
+ functional subsets (red
events) were overlaid onto a density plot (black shading) of the memory phenotype, as determined by CD27, CD45RO, and CD57, of the total CD8
+ T-
cell population in three representative EC subjects. (B) The memory phenotype of Gag-, Pol-, and Nef-specific perforin
+ functional subsets, as
determined by CD27, CD45RO, and CD57, was determined for all EC. Bars represent the mean and error bars indicate the standard deviation. (C) Gag-,
Pol-, and Nef-specific CD8
+ T-cells, as defined by the production of IFN-c or TNFa (green events), were overlaid onto a density plot (black shading) of
the memory phenotype, as determined by CD27 and CD45RO, of the total CD8
+ T-cell population in three separate EC and CP subjects. (D) Gag- and
CEF-specific CD8
+ T-cells, as defined by the production of IFN-c or TNFa (green events), were overlaid onto a density plot (black shading) of the
memory phenotype, as determined by CD27 and CD45RO, of the total CD8
+ T-cell population in two separate CP subjects. (A, C, D) Percentages
represent the fraction of overlaid cells that fall within each quadrant.
doi:10.1371/journal.ppat.1000917.g004
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+) yet remained
perforin
+ after six hours of stimulation. These CD8
+ T-cells that
co-expressed CD107a and perforin likely upregulated new
perforin; they have presumably lost most or all of their pre-
formed perforin through the process of degranulation. By
analyzing this specific population, we found that the proportion
of the HIV-specific CD8
+ T-cell response in EC that co-expressed
CD107a
+ and perforin
+ was significantly higher than CP to all
HIV antigens. However, we have also shown that newly
synthesized perforin largely bypasses cytotoxic granules [23];
therefore, we are almost certainly underestimating the levels of
perforin upregulation by focusing only on cells that have
degranulated.
The capacity of unstimulated CD8
+ T-cells from EC to begin to
eliminate HIV-infected autologous CD4
+ T-cell targets within
several hours of co-incubation has been previously reported [14].
The results from this study suggested that HIV-specific CD8
+ T-
cells were responsible for the elimination of infected CD4
+ T-cells
through a mechanism dependent on cell-to-cell contact and MHC-I
restriction. Our findings on perforin upregulation by HIV-specific
CD8
+ T-cells shortly after stimulation are consistent with the results
of Saez-Cirion and colleagues [14] and may even be a mechanism
to explain their findings. Moreover, another previously published
report indicated that HIV-specific CD8
+ T-cells kill targets through
the use of cytotoxicgranules and not by the Fas/FasL pathway [48].
Therefore, available evidence indicates that the perforin/granzyme
pathway of cytotoxicity is likely the primary means by which HIV-
specific CD8
+ T-cells kill infected cells in vivo.
Our findings here suggest that HIV-specific CD8
+ T-cells in EC
have a superior cytotoxic potential by expressing higher levels of
Figure 5. Inverse relationship between viral load and HIV-specific perforin expression, which is not rescued by HAART. (A) The
average proportion of HIV-specific perforin expression within each subject was plotted against the HIV viral load from each respective subject. The
most proximal viral load measurement to the time point of the PBMC sample was used in the analysis. Spearman correlation tests (nonparametric;
two-tailed) were performed to determine statistical significance. (B) The relative contribution of perforin to the Gag-, Pol-, and Nef-specific CD8
+ T-cell
responses is shown for all EC, CP, VNP, and HAART-suppressed subjects. Each symbol represents an individual study subject. One-way ANOVA tests
(nonparametric; Kruskal-Wallis test) were performed followed by a Dunns test for multiple comparisons. * denotes a p value ,0.05, ** denotes a
p value ,0.01, and *** denotes a p value ,0.001. The error bars represent the mean and standard deviation.
doi:10.1371/journal.ppat.1000917.g005
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Migueles and colleagues [17]. These authors showed that HIV-
specific CD8
+ T-cells from EC accumulate more granule-
associated perforin as a result of their superior ability to proliferate
in vitro compared to CD8
+ T-cells from progressors. They also
found that higher amounts of perforin (and granzyme B) in HIV-
specific cells translate into an enhanced ability to lyse infected
targets. Thus, together with the previous work of Migueles et al.,
our results show that EC have an enhanced ability to upregulate
perforin either directly ex vivo or after in vitro proliferation. Given
what is known about the importance of perforin in orchestrating
cytotoxicity, we can conclude that HIV-specific CD8
+ T-cells from
EC certainly have the potential to elicit elimination of infected
targets to a greater degree than progressors, which may directly
impact viral load. Furthermore, we know that newly synthesized
perforin traffics directly to the immunological synapse - the site of
action of cytotoxicity [23].
Besides differences in cytotoxic capabilities, HIV-specific CD8
+
T-cells from EC have also been shown to be more polyfunctional
in nature; they can simultaneously degranulate and produce
multiple functional molecules, such as IL-2, IFN-c, and TNFa,t o
a greater extent than CD8
+ T-cells from progressors [8,49]. Our
results here confirm and extend these findings. Polyfunctional
HIV-specific CD8
+ T-cells were also found in this study to
comprise a greater fraction of the response in EC than in CP.
Interestingly, we rarely observed HIV-specific CD8
+ T-cells
capable of producing all six functions simultaneously. This results
from a dichotomous relationship between perforin and IL-2
production from the same cell [30]. The implications of this
dichotomy are profound for our understanding of effective HIV-
specific CD8
+ T-cell responses: IL-2 producing CD8
+ T-cells will
presumably not have immediate cytolytic activity; conversely,
perforin producing CD8
+ T-cells may be inherently reliant upon
production of IL-2 from cells in their surrounding environment for
maintenance or modulation. Both cell types are most likely crucial
to maintaining protective immunity. The IL-2 producing cells may
be part of a population of CD8
+ T-cells that can maintain itself
through autocrine production of IL-2. This ability may be
important in the setting of diminished CD4
+ T-cell help in HIV
infection [10]. Alternatively, these cells may represent a self-
renewing memory population of CD8
+ T-cells responsible for
long-term maintenance of effector cells. IL-2 producing cells likely
do not display any direct anti-viral capability directly after
activation [30] but may be able to differentiate into perforin
producing effector cells. The increased IL-2 production observed
by both HIV-specific CD8
+ T-cells and CD4
+ T-cells [42] in EC
may also directly increase cytotoxic potential, as has recently been
reported [50,51].
Interestingly, we found that a substantial fraction of the total
perforin production by HIV-specific CD8
+ T-cells among EC
comes not from polyfunctional populations but instead from cells
that elicit only a single other measured functional parameter:
specifically MIP1a or CD107a. In previous studies, where
perforin upregulation was not measured, the potential importance
and cytotoxic capabilities of these populations was not appreci-
ated. On this note, the degree of functionality of a CD8
+ T-cell
response is only reflective of what functional parameters are
actually being measured. For example, we find that most CD8
+ T-
cells that upregulate perforin also produce granzyme B upon
stimulation [30]. Therefore, many of the CD8
+ T-cells found in
this study to co-express perforin with MIP1a and/or CD107a,
may actually be highly ‘‘polyfunctional’’ if we had also examined
the expression of other parameters critical for cytotoxicity, such as
granzyme B.
Our data show that perforin expressing cells bear effector-like
phenotypic markers. Thus, while a central memory phenotype is
often considered a protective phenotype in HIV infected
individuals, our results suggest that effector cells are also of
significance. It should be noted, however, that simply achieving
effector status does not guarantee the expression of perforin.
Indeed, some HIV-specific CD8
+ T-cells in both EC and CP were
CD27
-CD45RO
- yet did not express perforin. Our results suggest
that effector status is necessary but not sufficient for perforin
upregulation. The importance of effector cells in the control of
HIV infection is further supported by recent observations by
Picker and colleagues who found that a rhesus-CMV-based SIV
vaccine vector could stimulate protective effector SIV-specific
CD8
+ T-cells [52].
Our results suggest that perforin expression by HIV-specific
CD8
+ T-cells is not readily recovered by inhibition of viral
replication or reduction in chronic immune activation by HAART
- a finding which is consistent with a previous report showing that
HAART treatment does not restore other functional parameters,
such as proliferative capacity, polyfunctionality, or cytotoxic
capacity [53]. We also found that perforin production does not
appear to be directly influenced by beneficial HLA-B haplotypes
or the relative maintenance of CD4
+ T-cell levels over time.
Whether perforin expression is lost early, late, or progressively
during infection remains unclear. Further studies are necessary to
identify the mechanism(s) underlying the relative absence of
perforin upregulation in progressive HIV infection, and, if
possible, to discover a means by which this critical function can
be regained or elicited through therapeutic intervention.
Materials and Methods
Ethics statement
Blood specimens were acquired with the written informed
consent of all study patients and with the approval of the
institutional review board at each respective institution where
patient materials were collected: University of Pennsylvania
(IRB# 809316), University Hospitals Case Western Medical
Center (IRB# FWA00003937), University of Alabama at
Birmingham (IRB# X090708004), University of Toronto and
St. Michael’s Hospital (IRB# 07-106), and Harvard University
(IRB# 2003-P-001894 and IRB# 2003-P-001678/75). The study
was conducted following the principles stipulated in the Declara-
tion of Helsinki.
Human subjects
We examined ex vivo HIV-specific CD8
+ T-cell responses from
35 elite controllers (EC), 29 viremic controllers (VC), 27 chronic
progressors (CP), and 6 viremic nonprogressors (VNP). Most EC
and VC were recruited from outpatient clinics at local Boston
hospitals as well as from providers throughout the United States
[54]. Several EC were also recruited from clinics associated with
the University of Toronto. PBMC samples from CP were from
clinics associated with the University of Pennsylvania Center for
AIDS Research, the University of Toronto, Case Western Reserve
University, and the University of Alabama at Birmingham. VNP
samples were obtained from the University of Toronto and Case
Western Reserve University. PBMC samples from 15 HAART-
suppressed patients were obtained from Harvard University and
the University of Toronto.
EC were defined by consistent plasma HIV RNA levels below
the limit of detection (e.g. ,75 copies/mL by bDNA or ,50
copies/mL by ultrasensitive PCR) in a minimum of three
determinations of plasma HIV RNA spanning at least a 12-
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and 2,000 copies/mL, while the majority of viral load measure-
ments of CP were above 10,000 copies/mL. CD4
+ T-cell counts
were not considered for inclusion criteria in the EC, VC, or CP
groups. VNP were identified as subjects with consistently high
viremia (above 10,000 copies/mL on average) but with relatively
stable CD4
+ T-cell counts after long-term infection. It is the
relative preservation of CD4
+ T-cell numbers in spite of sustained
high level HIV replication that was used to distinguish the VNP
group clinically from CP. All subjects from the EC, VC, CP, and
VNP groups were off antiretroviral therapy for at least 6 months
prior to the sampling date; yet most subjects were treatment-naive.
Refer to Table 1 and Table S1 for more detailed information on
the study cohort.
Antibodies
The following antibodies were used in this study: anti-CD4 PE
Cy5.5, anti-CD14 APC Alexa 750, anti-CD19 APC Alexa 750,
anti-CD8 Texas Red-PE, anti-IFN-c Alexa 700 (Invitrogen,
Carlsbad, CA), anti-CD107a FITC, anti-IL-2 APC, anti-TNFa
PE Cy7 (BD Pharmingen, San Diego, CA), anti-MIP1a PE (R&D
Systems, Minneapolis, MN), anti-CD27 PE Cy5 (Beckman
Coulter, Fullerton, CA), anti-CD57 Qdot 565, anti-CD3 Qdot
585, and anti-CD45RO Qdot 605 or 705 (custom). Custom
conjugations to Quantum (Q) dot nanocrystals were performed in
our laboratory with reagents purchased from Invitrogen. The anti-
perforin antibody (B-D48 clone) was purchased from Diaclone
(Besancon, France) and conjugated to Pacific Blue (Invitrogen) in
our laboratory.
PBMC stimulation assays
Cryopreserved PBMC were thawed and subsequently rested
overnight at 37uC, 5% CO2 in complete medium (RPMI
supplemented with 10% FBS and 1% L-glutamine). The following
morning, the cells were washed with complete medium and
resuspended at a concentration of 2610
6 cells/mL if sufficient cell
numbers were available. Costimulatory antibodies (anti-CD28 and
anti-CD48d; each at 1 mg/ml final concentration; BD Biosciences;
San Jose, California), monensin (1 mg/ml final concentration; BD
Biosciences; San Jose, California) and Brefeldin A (1 mg/ml final
concentration; Sigma-Aldrich; St. Louis, Missouri) were also
added to each condition. Anti-CD107a was added at the start of
all stimulation periods, as described previously [28]. PBMC were
incubated at 37uC, 5% CO2 for six hours with overlapping 15-mer
peptide pools encompassing HIV-1 (clade B) Gag, Pol, Env, Nef,
and the viral accessory proteins (TRVVV) [as 5 separate
conditions]. PBMC from many of the subjects were also stimulated
with a CEF peptide pool, which contains peptides derived from
CMV, EBV, and Influenza virus. Each individual peptide in the
pools was at a final concentration of 2 mg/mL for all stimulations.
At the end of six hours, cells were stained with Aqua amine-
reactive dye (Invitrogen; Carlsbad, California) for 15 minutes in
the dark at room temperature in order to later identify viable cells.
A cocktail of antibodies was then added to the cells to stain for
surface markers for an additional 20 minutes. Following staining
for cell surface molecules, cells were permeabilized using the
Cytofix/Cytoperm kit (BD Biosciences; San Jose, California)
according to the manufacturer’s instructions. A cocktail of
antibodies against intracellular markers was then added to the
cells and allowed to incubate for one hour in the dark at room
temperature. Finally, cells were fixed in 1x PBS containing 1%
paraformaldehyde (Sigma-Aldrich; St. Louis, Missouri) before
being stored in the dark at 4uC until the time of collection on the
flow cytometer.
Flow cytometric analysis
For each stimulation condition, at least 500,000 total events
were acquired using a modified LSRII (BD Immunocytometry
Systems, San Jose, California). Data analysis was performed using
FlowJo (version 8.8.4; TreeStar, Ashland, Oregon) and Spice
(version 4.2.3, Dr. Mario Roederer, NIH, Bethesda, Maryland).
Reported data have been corrected for background, and only
responses with a total frequency above 0.25% of memory CD8
+ T-
cells (after background subtraction) were considered for analysis.
Boolean gating analysis was carried out once positive gates were
established for each functional parameter. This analysis resulted in
64 possible combinations of the 6 measured functions. Important-
ly, two combinations were ignored in all analyses: (1) events
negative for all measured functional parameters and (2) perforin
single-positive cells. By analyzing the data in such a manner, we
only examined perforin expression resulting from HIV-specific
stimulation. For this reason, perforin expression was only
considered within activated, HIV-specific CD8
+ T-cells expressing
at least one other functional parameter. Refer to Figure S1A for
further information on the gating strategy. As indicated by the
gating strategy, naı ¨ve cells (CD27
+CD45RO
-) were excluded when
performing all analyses except for the memory phenotyping data
presented in Figure 4.
Statistical analysis
All graphing and statistical analysis was performed using R
(version 2.8.1), JMP (version 7), or GraphPad Prism software
(version 5.0a). Functionality was compared between study groups
using nonparametric tests (Mann-Whitney test for two groups;
Kruskal-Wallis test followed by a Dunns test for multiple
comparisons when comparing three or more groups). Correlations
between viral load or CD4
+ T-cell counts and perforin expression
were based on Spearman correlation coefficients. Comparisons
between groups of specific functional permutations were based on
a Lachenbruch’s Two-part Wilcoxon test. This analysis simulta-
neously tests for a difference in the proportion of subjects who
have an above zero response and a difference in the magnitude of
the response [55,56]. Only those functional combinations for
which the average response was greater than zero were considered
to be relevant for consideration. Functional permutations were
considered significantly different if the p value was below 0.01. In
all figures, * denotes a p value ,0.05, ** denotes a p value ,0.01,
and *** denotes a p value ,0.001. Unless otherwise noted, error
bars represent the standard deviation.
Supporting Information
Figure S1 Perforin upregulation can be detected using a
polychromatic flow cytometric staining panel. (A) The
gating strategy from a representative subject: PBMC from an EC
were stimulated with SEB for six hours and then stained for six
CD8
+ T-cell functions (perforin, CD107a, IFN-c, IL-2, TNFa,
and MIP1a) along with lineage (CD14, CD19, CD3, CD4, CD8)
and memory (CD27, CD45RO, and CD57) markers. The no
stimulation control is also shown. (B) PBMC were stimulated with
SEB for six hours in the presence of BFA and monensin. Perforin
was stained either using the dG9 (left) or B-D48 (right) antibody
clones. The red box denotes granule-associated perforin within the
population of CD8
+ T-cells that did not respond to SEB
stimulation (i.e. resting CD8
+ T-cells not producing IFN-c). The
black box denotes a population of CD8
+ T-cells expressing both
perforin and IFN-c that can be detected using the B-D48 clone in
a conventional ICS assay.
Found at: doi:10.1371/journal.ppat.1000917.s001 (0.60 MB TIF)
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than CP. In addition to the relative contribution of perforin to
the HIV-specific CD8
+ T-cell response, EC also demonstrate
higher perforin magnitude. Total perforin production induced by
each HIV antigen pool is represented as the frequency of CD8
+ T-
cells (excluding naı ¨ve cells). One-way ANOVA tests (nonparamet-
ric; Kruskal-Wallis test) were performed followed by a Dunns test
for multiple comparisons. * denotes a p value , 0.05, ** denotes a
p value , 0.01, and *** denotes a p value , 0.001. All bars
represent the mean and error bars indicate the standard deviation.
Found at: doi:10.1371/journal.ppat.1000917.s002 (0.08 MB TIF)
Figure S3 There is no association between HIV re-
sponse magnitude and corresponding perforin expres-
sion. The Gag-, Pol-, and Nef-specific response magnitude (as the
frequency of CD8
+ T-cells; excluding naı ¨ve cells) is plotted against
the corresponding proportion of perforin expression for each
CD8
+ T-cell response among all EC subjects. Spearman
correlation tests (nonparametric; two-tailed) revealed no statisti-
cally significant relationship.
Found at: doi:10.1371/journal.ppat.1000917.s003 (0.16 MB TIF)
Figure S4 EC demonstrate some variability in HIV-
specific perforin expression. The relative contribution of
perforin for the CD8
+ T-cell response to each HIV antigen pool is
shown for a selected subset of EC. Each symbol represents a
different EC subject, and symbols of the same color represent
responses from the same individual. These subjects were chosen
partly because they mounted a positive response to all five HIV
peptide pools.
Found at: doi:10.1371/journal.ppat.1000917.s004 (0.06 MB TIF)
Figure S5 Breakdown of the average Nef-specific re-
sponse from EC, VC, and CP into all 64 possible
functional permutations. The entire response was broken
down into the contribution of each functional combination for the
average Nef-specific CD8
+ T-cell response. Note that two
functional permutations are ignored in the analysis: perforin single
positive and all negative. All bars represent the mean and error
bars indicate the standard deviation.
Found at: doi:10.1371/journal.ppat.1000917.s005 (0.14 MB TIF)
Figure S6 EC have an increased capacity for de novo
perforin synthesis. The proportion of the CD8
+ T-cell
response comprised of every CD107a
+perforin
+ functional subset
was calculated for all HIV antigens in EC, VC, and CP. One-way
ANOVA tests (nonparametric; Kruskal-Wallis test) were per-
formed followed by a Dunns test for multiple comparisons.
* denotes a p value , 0.05, ** denotes a p value , 0.01, and
*** denotes a p value , 0.001. All bars represent the mean and
error bars indicate the standard deviation.
Found at: doi:10.1371/journal.ppat.1000917.s006 (0.10 MB TIF)
Figure S7 Perforin expression is not restricted to the
presence of protective HLA-B alleles. EC were stratified
based on the expression of HLA-B alleles previously shown to be
associated with improved clinical outcomes. The relative amount
of perforin expression is shown for the Nef-specific CD8
+ T-cell
responses among all EC. Each symbol represents an individual
study subject. Some of the symbols are colored to denote the
presence of another protective HLA-B allele: blue, HLA-B13;
green, HLA-B15; orange, HLA-B51; red, HLA-B58. No statisti-
cally significant differences were found between the groups using a
one-way ANOVA test (nonparametric; Kruskal-Wallis) followed
by a Dunns test for multiple comparisons. The error bars represent
the mean and standard deviation.
Found at: doi:10.1371/journal.ppat.1000917.s007 (0.21 MB TIF)
Figure S8 EC display an expansion of CD27
-CD45RO
-
effector HIV-specific CD8
+ T-cells. The memory phenotype,
based on the surface expression of CD27 and CD45RO, was
determined for the average HIV-specific CD8
+ T-cell response, as
defined by the production of IFN-c or TNFa, among EC and CP.
Mann-Whitney tests (nonparametric; two-tailed) were performed
for each phenotypic combination. ** denotes a p value , 0.01. All
bars represent the mean and error bars indicate the standard
deviation.
Found at: doi:10.1371/journal.ppat.1000917.s008 (0.09 MB TIF)
Figure S9 Negative correlation between HIV-specific
perforin expression and viral load when considering
only VC, CP, and VNP subjects. The average percentage of
HIV-specific perforin expression from CD8
+ T-cells within each
subject was plotted against the HIV viral load among all subjects
excluding EC. The most proximal viral load measurement to the
time point of the PBMC sample was used in the analysis.
Spearman correlation tests (nonparametric; two-tailed) were
performed to determine statistical significance.
Found at: doi:10.1371/journal.ppat.1000917.s009 (0.09 MB TIF)
Figure S10 Positive correlation between HIV-specific
perforin expression and peripheral blood CD4
+ T-cell
counts. The percentage of Gag-, Pol-, and Nef-specific perforin
expression within each subject was plotted against CD4
+ T-cell
counts. The average percentage of HIV-specific perforin expres-
sion within each individual was also plotted against CD4
+ T-cell
counts. The most proximal CD4
+ T-cell count to the time point of
the PBMC sample was used in the analysis. Spearman correlation
tests (nonparametric; two-tailed) were performed to determine
statistical significance.
Found at: doi:10.1371/journal.ppat.1000917.s010 (0.17 MB TIF)
Figure S11 Not all functional parameters are correlated
with control of HIV replication. The proportion of each
measured functional parameter (except perforin) comprising the
average HIV-specific CD8
+ T-cell response in each subject was
plotted against the HIV viral load from each respective subject.
The most proximal viral load measurement to the time point of
the PBMC sample was used in the analysis. Spearman correlation
tests (nonparametric; two-tailed) were performed to determine
statistical significance.
Found at: doi:10.1371/journal.ppat.1000917.s011 (0.31 MB TIF)
Figure S12 HIV-specific CD8
+ T-cell response magni-
tude is slightly higher in EC than HAART-treated
individuals. The CD8
+ T-cell response magnitude to Gag,
Pol, and Nef peptide pools was calculated for EC and HAART-
treated subjects and plotted as percent of CD8
+ T-cells (excluding
naı ¨ve cells). The total magnitude was calculated by summing
across all functional combinations. Mann-Whitney tests (nonpara-
metric; two-tailed) were performed for each HIV antigen.
** denotes a p value , 0.01. All bars represent the mean and
error bars indicate the standard deviation.
Found at: doi:10.1371/journal.ppat.1000917.s012 (0.06 MB TIF)
Figure S13 The HIV-specific CD8
+ T-cell response
between EC and HAART-treated subjects does not vary
greatly in degranulation, cytokine production, or che-
mokine expression. The proportion of the average HIV-
specific CD8
+ T-cell response comprised of each single functional
parameter (except perforin) is shown among EC and HAART-
treated subjects. Mann-Whitney tests (nonparametric; two-tailed)
were performed for each functional parameter. * denotes a p value
, 0.05. All bars represent the mean and error bars indicate the
standard deviation.
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Table S1 Complete study cohort with relevant clinical
parameters.
Found at: doi:10.1371/journal.ppat.1000917.s014 (1.50 MB TIF)
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